Skip to main content
Premium Trial:

Request an Annual Quote

Arima Genomics Closes $7M Series B Round

NEW YORK - Arima Genomics said on Tuesday it has fetched $7 million in a Series B financing round.

The San Diego-based 3D genomics company said it will use the funds to expand its product portfolio and bioinformatics capabilities to "serve a broader spectrum of scientific and translational medicine applications." Additionally, the company will also use the money to ramp up its operational and commercial capacity worldwide.

New investors in this round include Genetron Health, Tech Coast Angels, Ladder Ventures, and Hiaqua Investments, joined by existing investors Agilent Technologies, Co-win Ventures, Vectr Ventures, and Berkeley Catalyst Fund.

"Arima Genomics' relationship with its more than 600 global customers is a testament to both its humble, science-led culture and the applicability of its product portfolio in driving discovery in critical clinical research programs," said Genetron Health CSO Hai Yan in a statement.

According to Arima CEO and Cofounder Siddarth Selvaraj, the company's 3D genomics technology has helped its customers publish more than 200 peer-reviewed studies to date, spanning the fields of cancer, neurobiology, immunology, and other complex diseases.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.